References

1. Przuntek H, Muller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm. 111: 201-216, 2004.

2. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm. Suppl. 46: 15-31, 1995.

3. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol. 44: S115-S120, 1998.

4. Gerlach M, Blum-Degen D, Lan J, Riederer P. Nitric oxide in the pathogenesis of Parkinson's disease. Adv Neurol. 80: 239-245, 1999.

5. Foley P, Riederer P. Pathogenesis and preclinical course of Parkinson's disease. J Neural Transm. Suppl. 56: 31-74, 1999.

6. Przuntek H, Muller T. Clinical efficacy of budipine in Parkinson's disease. J Neural Transm. Suppl. 56: 75-82, 1999.

7. Fox MJ. Lucky Man a memoir, Random house, New York, 2002.

8. Horowski R, Horowski L, Vogel S, Poewe W, Kielhorn FW. An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient. Neurology 45: 565-568, 1995.

9. Muller T. Mood disorders in early Parkinson's disease. Curr Opin Psychiatry 17: 191-196, 2004.

10. Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 15: 669-677, 2000.

11. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol. 249(Suppl. 3): III/1-III/5, 2002.

12. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 110: 517-536, 2003.

13. Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol. 53: 617-624, 1996.

14. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson's disease. N Engl J Med. 351: 2498-3508, 2004.

15. Foley P, Mizuno Y, Nagatsu T, Sano A, Youdin MBH, McGeer P, McGeer E, Riederer P. The l-DOPA story - an early Japanese contribution. Parkinsonism Relat Disord. 6: 1, 2000.

16. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism - chronic treatment with l-dopa. N Engl J Med. 280: 337-345, 1969.

17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184, 1992.

18. Muller T, Benz S, Bornke C, Russ H, Przuntek H. Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease. J Neural Transm. 110: 603-609, 2003.

19. Korczyn AD. Parkinson's disease: one disease entity or many? J Neural Transm. Suppl. 56: 107-111, 1999.

20. Muhlack S, Woitalla D, Welnic J, Twiehaus S, Przuntek H, Muller T. Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci Lett. 363: 284-287, 2004.

21. Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 61: 1563-1568, 2004.

22. Olanow CW, Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 62: S72-S81, 2004.

23. Smith LA, Jackson MJ, Al Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord. 20: 306-314, 2005.

24. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 62: 905-910, 2005.

25. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62: S47-S55, 2004.

26. Gershanik O, Emre M, Bernhard G, Sauer D. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 27: 963-971, 2003.

27. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol. 47: S122-S129, 2000.

28. Durif F. Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging 14: 337-345, 1999.

29. Ekesbo A, Rydin E, Torstenson R, Sydow O, Laengstrom B, Tedroff J. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 52: 120-125, 1999.

30. Fahn S. Is levodopa toxic? Neurology 47: S184-S195, 1996.

31. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med. 328: 176-183, 1993.

32. Przuntek H, Conrad B, Dichgans J, Kraus PH, Krauseneck P, Pergande G, Rinne U, Schimrigk K, Schnitker J, Vogel HP. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol. 6: 141-150, 1999.

33. Ben Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58: 293-299, 1995.

34. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of l-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol. 20: 55-66, 1997.

35. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Muller T. Hyperhomocysteinaemia in Parkinson's disease [letter]. J Neurol. 245: 811-812, 1998.

36. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Buttner T, Woitalla D, Muller T. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol. 40: 225-227, 1998.

37. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, Nappi G. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin Chem. 47: 1102-1104, 2001.

38. Kuhn W, Hummel T, Woitalla D, Muller T. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 56: 281-282, 2001.

39. Muller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett. 308: 54-56, 2001.

40. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55: 437-440, 2000.

41. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease [letter]. Lancet 354: 126-127, 1999.

42. Muller T, Woitalla D, Kuhn W. Benefit of folic acid supplementation in parkinsonian patients treated with levodopa. J Neurol Neurosurg Psychiatry 74: 549, 2003.

43. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction [letter]. Lancet 3: 351(9095): 36-37, 1998.

44. Perry IJ. Homocysteine and risk of stroke. J Cardiovasc Risk 6: 235-240, 1999.

45. Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26: 361-371, 2005.

46. Muller T. Non-dopaminergic drug treatment of Parkinson's disease. Exp Opin Pharmacother. 2: 557-572, 2001.

47. Muller T, Renger K, Kuhn W. Levodopa associated homocysteine increase and sural axonal neurodegeneration. Arch Neurol. 61: 657-660, 2004.

48. Muller T. Non-dopaminergic drug treatment of Parkinson's disease. Expert Opin Pharmacother. 2: 557-572, 2001.

49. Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, Takeshima T, Sasaki K, Nakashima K. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with l-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci. Mar; 207(1-2): 19-23, 2003.

50. Woitalla D, Kuhn W, Muller T. MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson's disease. J Neural Transm. Suppl: 15-20, 2004.

51. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol. 60: 59-64, 2003.

52. Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H. Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 58: 1539-1541, 2002.

53. Huang G, Dragan M, Freeman D, Wilson JX. Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons. Glia 51: 47-55, 2005.

54. Tissingh G, Berendse HW, Bergmans P, DeWaard R, Drukarch B, Stoof JC, Wolters EC. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord. 16: 41-46, 2001.

55. Muller A, Mungersdorf M, Reichmann H, Strehle G, Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci. 9: 521-524, 2002.

56. Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H. Detection of presymp-tomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord. 19: 1196-1202, 2004.

57. Isobe C, Murata T, Sato C, Terayama Y. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci. 77: 1836-1843, 2005.

58. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 58: 1471-1475, 2002.

59. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of l-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 60: 1125-1129, 2003.

60. Sachdev P. Homocysteine, cerebrovascular disease and brain atrophy. J Neurol Sci. 226: 25-29, 2004.

61. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem. 80: 101-110, 2002.

62. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord. 11: 253-256, 2005.

63. Ostrem JL, Kang GA, Subramanian I, Guarnieri M, Hubble J, Rabinowicz AL, Bronstein J. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 64: 1482, 2005.

64. Nissinen E, Nissinen H, Larjonmaa H, Vaananen A, Helkamaa T, Reenila I, Rauhala P. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm. Sep; 112(9): 1213-1221, 2004.

65. Heider I, Lehmensiek V, Lenk T, Muller T, Storch A. Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures. J Neural Transm. Suppl. 68: 1-13, 2004.

66. Storch A, Blessing H, Bareiss M, Jankowski S, Ling ZD, Carvey P, Schwarz J. Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons. Mol Pharmacol. 57: 589-594, 2000.

67. Naoi M, Maruyama W, Nakao N, Ibi T, Sahashi K, Benedetti MS. (R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes. Ann Neurol. 43: 212-216, 1998.

68. Williams AC, Ramsden DB. Autotoxicity, methylation and a road to the prevention of Parkinson's disease. J Clin Neurosci. 12: 6-11, 2005.

69. AoyamaK, MatsubaraK, Okada K, Fukushima S, Shimizu K, Yamaguchi S, UezonoT, Satomi M, Hayase N, Ohta S, Shiono H, Kobayashi S. N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test. J Neural Transm. 107: 985-995, 2000.

70. Aoyama K, Matsubara K, Kondo M, Murakawa Y, Suno M, Yamashita K, Yamaguchi S, Kobayashi S. Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurosci Lett. 298: 78-80, 2001.

71. Müller T, Sallstrom BS, Haussermann P, Woitalla D, Rommelspacher H, Przuntek H, Kuhn W. Plasma levels of R- and S-salsolinol are not increased in "de-novo" Parkinsonian patients. J Neural Transm. 105: 239-246, 1998.

72. Muller T, Sallstrom BS, Haussermann P, Przuntek H, Rommelspacher H, Kuhn W. R- and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patients. J Neurol Sci. 164: 158-162, 1999.

73. Kuhn W, Woitalla D, Gerlach M, Russ H, Muller T. Tolcapone and neurotoxicity in Parkinson's disease. Lancet 352: 1313-1314, 1998.

74. Matsubara K, Aoyama K, Suno M, Awaya T. N-methylation underlying Parkinson's disease. Neurotoxicol Teratol. 24: 593-598, 2002.

75. Russ H, Muller T, Woitalla D, Rahbar A, Hahn J, Kuhn W. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol. 360: 719-720, 1999.

76. Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res. 29: 99-111, 1997.

77. Muller T, Kuhn W, Przuntek H. Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J Neural Transm Gen Sect. 92: 187-195, 1993.

78. Charlton CG, Crowell Jr. B. Striatal dopamine depletion, tremors, and hypokinesia following the intracra-nial injection of S-adenosylmethionine: a possible role of hypermethylation in parkinsonism. Mol Chem Neuropathol. 26: 269-284, 1995.

79. O'Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey Jr. RB, Bottiglieri T, Diaz-Arrastia R. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol. 61: 865-868, 2004.

80. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol. 53: 538-542, 1996.

Unraveling Alzheimers Disease

Unraveling Alzheimers Disease

I leave absolutely nothing out! Everything that I learned about Alzheimer’s I share with you. This is the most comprehensive report on Alzheimer’s you will ever read. No stone is left unturned in this comprehensive report.

Get My Free Ebook


Post a comment